A Phase 3 interventional study of Udenafil in Single Ventricle Heart Disease, sponsored by Mezzion Pharma Co. Ltd. Completed at 17 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-10-14.
Sponsored by Mezzion Pharma Co. Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to evaluate the efficacy of MZ101 therapy in reducing liver stiffness.
This is open-label, long-term prospective study in a cohort of Fontan subjects taking drug daily for one year. The study will determine the scope of hepatic stiffness in the cohort by ultrasound and magnetic resonance imaging elastography and evaluate MZ101 pharmacotherapy as a potentially efficacious treatment to reduce liver stiffness.
Mezzion Pharma Co. Ltd is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who were receiving Udenafil 87.5 mg BID in FUEL study prior to enrolling to this study (FALD).
Drug: Udenafil
Subjects who were receiving Placebo BID in FUEL study prior to enrolling to this study (FALD).
Drug: Udenafil
Open-label extension with Udenafil 87.5 mg BID treatment for 52 weeks.
Effect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Ultrasound Shear Wave Elastography
Liver stiffness was measured at baseline and 52 weeks using Ultrasound Shear Wave Elastography (USWE) separately in Udenafil Continuation (U+) and Udenafil Naive (U-) groups. A decrease in value indicates a decrease in liver stiffness.
Time frame: 52 weeks
Effect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Magnetic Resonance Elastography
Liver stiffness was measured at baseline and 52 weeks using Magnetic Resonance Elastography (MRE) separately in Udenafil Continuation (U+) and Udenafil Naive (U-) groups. A decrease in value indicates a decrease in liver stiffness.
Time frame: 52 weeks
Effect of Udenafil 87.5 mg BID on Enhanced Liver Fibrosis (ELF) Score After 52 Weeks of Treatment
Overall ELF score. ELF score is based on the serum levels of hyaluronic acid (HA), amino-terminal propeptide of type III collagen (PIIINP), and tissue inhibitor of metalloproteinase-1 (TIMP-1), and calculated using the following formula: ELF score= 2.494+0.846 In(CHA)+0.391 In(CPIIINP)+0.391 In(CTIMP-1). The levels of each component were as assessed individually and as part of the calculated ELF score as continuous variables. The normal range in healthy subjects ≤20 years of age is 6.9 - 8.8. Correlations between ELF and the degree of liver fibrosis have not been established in patients with Fontan circulation, however, a decrease in ELF score is associated with improved liver health in other disease states.
Time frame: 52 weeks
Effect of Udenafil 87.5 mg BID on Brain Natriuretic Peptide After 52 Weeks of Treatment
Brain Natriuretic Peptide (BNP) was measured at baseline and 52 weeks of treatment. BNP is a biomarker of overall cardiac function across a variety of disease states. A decrease in value is associated with improved cardiac function.
Time frame: 52 weeks
| Milestone | Udenafil Continuation (U+) | Udenafil Naive (U-) |
|---|---|---|
| Started | 36 | 52 |
| Completed | 33 | 45 |
| Not completed | 3 | 7 |
Liver stiffness was measured at baseline and 52 weeks using Ultrasound Shear Wave Elastography (USWE) separately in Udenafil Continuation (U+) and Udenafil Naive (U-) groups. A decrease in value indicates a decrease in liver stiffness.
| meters per second | Udenafil Continuation (U+) | Udenafil Naive (U-) | Total Udenafil |
|---|---|---|---|
| Baseline | 1.91 ± 0.380 | 2.02 ± 0.450 | 1.97 ± 0.422 |
| Week 52 | 1.86 ± 0.288 | 1.96 ± 0.349 | 1.92 ± 0.325 |
Liver stiffness was measured at baseline and 52 weeks using Magnetic Resonance Elastography (MRE) separately in Udenafil Continuation (U+) and Udenafil Naive (U-) groups. A decrease in value indicates a decrease in liver stiffness.
| kiloPascal (kPa) | Udenafil Continuation (U+) | Udenafil Naive (U-) | Total Udenafil |
|---|---|---|---|
| Baseline | 5.26 ± 0.927 | 5.26 ± 1.453 | 5.26 ± 1.173 |
| Week 52 | 4.95 ± 1.080 | 5.50 ± 1.550 | 5.20 ± 1.322 |
Overall ELF score. ELF score is based on the serum levels of hyaluronic acid (HA), amino-terminal propeptide of type III collagen (PIIINP), and tissue inhibitor of metalloproteinase-1 (TIMP-1), and calculated using the following formula: ELF score= 2.494+0.846 In(CHA)+0.391 In(CPIIINP)+0.391 In(CTIMP-1). The levels of each component were as assessed individually and as part of the calculated ELF score as continuous variables. The normal range in healthy subjects ≤20 years of age is 6.9 - 8.8. Correlations between ELF and the degree of liver fibrosis have not been established in patients with Fontan circulation, however, a decrease in ELF score is associated with improved liver health in other disease states.
| score on a scale | Udenafil Continuation (U+) | Udenafil Naive (U-) | Total Udenafil |
|---|---|---|---|
| Baseline | 10.58 ± 0.915 | 10.45 ± 0.853 | 10.50 ± 0.877 |
| Week 52 | 9.72 ± 0.818 | 9.79 ± 0.750 | 9.76 ± 0.776 |
Brain Natriuretic Peptide (BNP) was measured at baseline and 52 weeks of treatment. BNP is a biomarker of overall cardiac function across a variety of disease states. A decrease in value is associated with improved cardiac function.
| pg/ml | Udenafil Continuation (U+) | Udenafil Naive (U-) | Total Udenafil |
|---|---|---|---|
| Baseline | 16.89 ± 13.726 | 17.20 ± 13.428 | 17.07 ± 13.464 |
| Week 52 | 20.31 ± 18.336 | 20.78 ± 19.165 | 20.59 ± 18.698 |
Collected over Not applicable, as all safety information was collected in the Study PHN-Udenafil-03 (parent study) and will be reported as part of the results from that study. All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed as part of Study PHN-Udenafil-04.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Udenafil 87.5 mg BID | — | — | — |
| Age, Customized(years) | Udenafil Continuation (U+) | Udenafil Naive (-) | Total |
|---|---|---|---|
| Mean | 15.80 ± 1.992 | 15.16 ± 1.961 | 15.4 ± 2.0 |
| Sex: Female, Male(Participants) | Udenafil Continuation (U+) | Udenafil Naive (-) | Total |
|---|---|---|---|
| Female | 13 | 19 | 32 |
| Male | 23 | 33 | 56 |
| Ethnicity (NIH/OMB)(Participants) | Udenafil Continuation (U+) | Udenafil Naive (-) | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 |
| Not Hispanic or Latino | 32 | 48 | 80 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Udenafil Continuation (U+) | Udenafil Naive (-) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 6 |
| White | 32 | 43 | 75 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Body Mass Index (BMI)(kilograms per meter squared) | Udenafil Continuation (U+) | Udenafil Naive (-) | Total |
|---|---|---|---|
| Mean | 21.9 ± 4.552 | 21.4 ± 4.174 | 21.6 ± 4.314 |
| Height(cm) | Udenafil Continuation (U+) | Udenafil Naive (-) | Total |
|---|---|---|---|
| Mean | 162.08 ± 10.277 | 164.89 ± 8.936 | 163.74 ± 9.552 |
| Weight(Kg) | Udenafil Continuation (U+) | Udenafil Naive (-) | Total |
|---|---|---|---|
| Mean | 57.48 ± 13.078 | 58.42 ± 13.238 | 58.03 ± 13.105 |
| Liver Stiffness by Ultrasound Shear Wave Elastography (USWE)(meters/sec) | Udenafil Continuation (U+) | Udenafil Naive (-) | Total |
|---|---|---|---|
| Mean | 1.91 ± 0.380 | 2.02 ± 0.450 | 1.97 ± 0.422 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Sep 2020, 30 months.
Results were first posted in Sep 2025, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Udenafil
Mezzion Pharma Co. Ltd